Royalty Pharma plc (RPRX) announced Tuesday that it has acquired a pre-existing royalty interest in Nuvalent, Inc.'s (NUVL) neladalkib and zidesamtinib from an undisclosed third party for up to $315 million.
In pre-market activity on the Nasdaq, Royalty Pharma shares were gaining around 2.5 percent to trade at $39.48, while Nuvalent's shares were losing 0.3 percent, at $104.71.
Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors or TKIs. The expected royalty duration for both therapies extends through approximately 2041 to 2042.
As per the analysts estimates, neladalkib sales would be around $3.5 billion and zidesamtinib sales would be around $1.9 billion by 2035.
Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer or NSCLC, while zidesamtinib is in development for ROS1 mutation-positive NSCLC.
The company expects both therapies to deliver a best-in-class combination of efficacy and tolerability.
In November, Nuvalent reported positive pivotal results for neladalkib in TKI pre-treated patients, demonstrating durable activity and a generally well-tolerated safety profile. Neladalkib is also being evaluated in an ongoing Phase 3 study in TKI-nave patients.
The company added that Zidesamtinib is currently undergoing review by the U.S. Food and Drug Administration and has an action date of September 18, 2026 for TKI pre-treated patients.
Zidesamtinib is also being assessed in an ongoing Phase 1/2 study in TKI-nave patients.
In the deal, Covington & Burling, Dechert and Maiwald acted as legal advisors to Royalty Pharma.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.